Claims

1. Use of a combination in the manufacture of a medicament for treating depression in a human subject with enhanced plasma levels of a dextromethorphan, wherein the human subject is an extensive metabolizer of the dextromethorphan and suffers from depression, wherein a daily dose of a combination is to be administered to the human subject, wherein the combination comprises:

1) a bupropion, and

2) the dextromethorphan,

wherein the combination is to be administered once or twice a day for at least eight consecutive days.

2. The use of claim 1 wherein the daily dose of the dextromethorphan is about 40 mg to about 350 mg.

3. The use of claim 2, wherein the daily dose of the dextromethorphan is about 40 mg to about 100 mg.

4. The use of claim 1, wherein a single dose of the dextromethorphan is about 40 mg to about 50 mg.

5. The use of claim 4, wherein a single dose of the dextromethorphan is about 42 mg to about 48 mg.

6. The use of claim 5, wherein a single dose of the dextromethorphan is about 44 mg to about 46 mg.

7. The use of claim 1, wherein the first C_{min} of the dextromethorphan is at least about 30 times the second C_{min} of the dextromethorphan.

8. The use of claim 1, wherein the first C_{min} of the dextromethorphan is at least about 40 times the second C_{min} of the dextromethorphan.

9. The use of claim 1, wherein the first C_{min} of the dextromethorphan is at least about 50 times the second C_{min} of the dextromethorphan.

10. The use of claim 1, wherein the first C_{min} of the dextromethorphan is about 20 ng/mL to about 70 ng/mL.

11. The use of claim 1, wherein the first C_{min} of the dextromethorphan is about 70 ng/mL to about 120 ng/mL.

12. The use of claim 4, wherein the first C_{min} of the dextromethorphan is about 115 ng/mL to about 200 ng/mL.

13. The use of claim 1, wherein the first C_{min} of the dextromethorphan is about 20 ng/mL to about 10,000 ng/mL.

14. The use of claim 1, wherein the daily dose of the bupropion is about 40 mg to about 300 mg.

15. The use of claim 1, wherein the daily dose of the bupropion is about 70 mg to about 220 mg.

16. The use of claim 1, wherein a single dose of the bupropion is about 70 mg to about 120 mg.

17. The use of claim 4, wherein a single dose of the bupropion is about 90 mg to about 150 mg.

18. The use of claim 1, wherein the bupropion or the dextromethorphan is deuterium-modified.

19. The use of claim 18, wherein the dextromethorphan is deuterium-modified.

20. The use of claim 1, wherein the bupropion and the dextromethorphan are to be co-administered as two separate dosage forms.

21. The use of claim 1, wherein the bupropion, and the dextromethorphan, are to be co-administered as a solid or liquid, in a single oral dosage form.

22. The use of claim 21, wherein the single oral dosage form is a solid.

23. The use of claim 22, wherein the single solid oral dosage form further comprises a binder, a disintegrating agent or a lubricant.

24. The use of claim 22, wherein the single solid oral dosage form is a tablet, a troche, a pill or a capsule.

25. The use of claim 21, wherein the single oral dosage form is a liquid.

26. The use of claim 25, wherein the single liquid oral dosage form comprises a liquid or a solid phase dispersion of the bupropion, and the dextromethorphan.

27. The use of claim 1, wherein the bupropion, and the dextromethorphan are to be co-administered to the human subject twice a day for at least 30 consecutive days.

28. The use of claim 1, wherein the bupropion and the dextromethorphan are to be co-administered to the human subject twice a day for at least 60 consecutive days.

CLAIMS

1. Use of dextromethorphan in the manufacture of a medicament for treating depression in a human being, wherein the medicament is to be co-administered with bupropion, and wherein the human being is an extensive metabolizer of dextromethorphan.

2. Use of claim 1, wherein bupropion is to be co-administered with dextromethorphan for at least eight consecutive days.

3. Use of claim 2, wherein, on the eighth day, dextromethorphan has a plasma level 12 hours after co-administration of bupropion with dextromethorphan that is at least 80 times the plasma level that would be achieved by administration of the same amount of dextromethorphan without co-administration of bupropion.

4. Use of any one of claims 1 to 3, wherein about 40 mg to about 140 mg of dextromethorphan is to be administered per day.

5. Use of claim 4, wherein about 60 mg to about 100 mg of dextromethorphan is to be administered per day.

6. Use of any one of claims 1 to 3, wherein about 100 mg to about 250 mg of bupropion is to be administered per day.

7. Use of any one of claims 1 to 3, wherein about 200 mg to about 250 mg of bupropion is to be administered per day.

8. Use of any one of claims 1 to 7, wherein bupropion is to be administered in an amount that results in a plasma concentration of dextromethorphan in the human being on the eighth day that is at least 10 times the plasma concentration of the same amount of dextromethorphan administered without bupropion.

9. Use of any one of claims 1 to 8, wherein bupropion is to be co-administered with dextromethorphan for the treatment of agitation.

10. Use of any one of claims 1 to 9, wherein the bupropion is to be co-administered with dextromethorphan in a single dosage form.